Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly

Nienke R. Biermasz, Alberto M. Pereira, Marijke Frölich, Johannes A. Romijn, Johannes D Veldhuis, Ferdinand Roelfsema

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Octreotide is a potent somatostatin analog that inhibits growth hormone (GH) release and restricts somatotrope cell growth. The long-acting octreotide formulation Sandostatin LAR is effective clinically in ∼60% of patients with acromegaly. Tumoral GH secretion in this disorder is characterized by increases in pulse amplitude and frequency, nonpulsatile (basal) release, and irregularity. Whether sustained blockade by octreotide can restore physiological secretion patterns in this setting is unknown. To address this question, we studied seven patients with GH-secreting tumors during chronic receptor agonism. Responses were monitored by sampling blood at 10-min intervals for 24 h, followed by analyses of secretion and regularity by multiparameter deconvolution and approximate entropy (ApEn). The somatostatin agonist suppressed GH secretory-burst mass, nonpulsatile (basal) GH release, and pulsatile secretion, thereby decreasing total GH secretion by 86% (range 70-96%). ApEn decreased from 1.203 ± 0.129 to 0.804 ± 0.141 (P = 0.032), denoting greater regularity. None of GH pulse frequency, basal GH secretion rates, or ApEn normalized. In summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive GH secretion in acromegaly. Presumptive tumoral autonomy is inferred by continued elevations of event frequency, overall pattern disruption (irregularity), and nonsuppressible basal GH secretion.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume286
Issue number1 49-1
StatePublished - Jan 2004

Fingerprint

Acromegaly
Octreotide
Growth Hormone
Entropy
Somatostatin
Cell growth
Deconvolution
Tumors
Blood
Sampling

Keywords

  • Deconvolution analysis
  • Diurnal rhythm
  • Growth hormone
  • Human

ASJC Scopus subject areas

  • Physiology
  • Endocrinology
  • Biochemistry

Cite this

Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. / Biermasz, Nienke R.; Pereira, Alberto M.; Frölich, Marijke; Romijn, Johannes A.; Veldhuis, Johannes D; Roelfsema, Ferdinand.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 286, No. 1 49-1, 01.2004.

Research output: Contribution to journalArticle

Biermasz, Nienke R. ; Pereira, Alberto M. ; Frölich, Marijke ; Romijn, Johannes A. ; Veldhuis, Johannes D ; Roelfsema, Ferdinand. / Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. In: American Journal of Physiology - Endocrinology and Metabolism. 2004 ; Vol. 286, No. 1 49-1.
@article{5849db403a1e47d5be2211d6c5db1732,
title = "Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly",
abstract = "Octreotide is a potent somatostatin analog that inhibits growth hormone (GH) release and restricts somatotrope cell growth. The long-acting octreotide formulation Sandostatin LAR is effective clinically in ∼60{\%} of patients with acromegaly. Tumoral GH secretion in this disorder is characterized by increases in pulse amplitude and frequency, nonpulsatile (basal) release, and irregularity. Whether sustained blockade by octreotide can restore physiological secretion patterns in this setting is unknown. To address this question, we studied seven patients with GH-secreting tumors during chronic receptor agonism. Responses were monitored by sampling blood at 10-min intervals for 24 h, followed by analyses of secretion and regularity by multiparameter deconvolution and approximate entropy (ApEn). The somatostatin agonist suppressed GH secretory-burst mass, nonpulsatile (basal) GH release, and pulsatile secretion, thereby decreasing total GH secretion by 86{\%} (range 70-96{\%}). ApEn decreased from 1.203 ± 0.129 to 0.804 ± 0.141 (P = 0.032), denoting greater regularity. None of GH pulse frequency, basal GH secretion rates, or ApEn normalized. In summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive GH secretion in acromegaly. Presumptive tumoral autonomy is inferred by continued elevations of event frequency, overall pattern disruption (irregularity), and nonsuppressible basal GH secretion.",
keywords = "Deconvolution analysis, Diurnal rhythm, Growth hormone, Human",
author = "Biermasz, {Nienke R.} and Pereira, {Alberto M.} and Marijke Fr{\"o}lich and Romijn, {Johannes A.} and Veldhuis, {Johannes D} and Ferdinand Roelfsema",
year = "2004",
month = "1",
language = "English (US)",
volume = "286",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1 49-1",

}

TY - JOUR

T1 - Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly

AU - Biermasz, Nienke R.

AU - Pereira, Alberto M.

AU - Frölich, Marijke

AU - Romijn, Johannes A.

AU - Veldhuis, Johannes D

AU - Roelfsema, Ferdinand

PY - 2004/1

Y1 - 2004/1

N2 - Octreotide is a potent somatostatin analog that inhibits growth hormone (GH) release and restricts somatotrope cell growth. The long-acting octreotide formulation Sandostatin LAR is effective clinically in ∼60% of patients with acromegaly. Tumoral GH secretion in this disorder is characterized by increases in pulse amplitude and frequency, nonpulsatile (basal) release, and irregularity. Whether sustained blockade by octreotide can restore physiological secretion patterns in this setting is unknown. To address this question, we studied seven patients with GH-secreting tumors during chronic receptor agonism. Responses were monitored by sampling blood at 10-min intervals for 24 h, followed by analyses of secretion and regularity by multiparameter deconvolution and approximate entropy (ApEn). The somatostatin agonist suppressed GH secretory-burst mass, nonpulsatile (basal) GH release, and pulsatile secretion, thereby decreasing total GH secretion by 86% (range 70-96%). ApEn decreased from 1.203 ± 0.129 to 0.804 ± 0.141 (P = 0.032), denoting greater regularity. None of GH pulse frequency, basal GH secretion rates, or ApEn normalized. In summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive GH secretion in acromegaly. Presumptive tumoral autonomy is inferred by continued elevations of event frequency, overall pattern disruption (irregularity), and nonsuppressible basal GH secretion.

AB - Octreotide is a potent somatostatin analog that inhibits growth hormone (GH) release and restricts somatotrope cell growth. The long-acting octreotide formulation Sandostatin LAR is effective clinically in ∼60% of patients with acromegaly. Tumoral GH secretion in this disorder is characterized by increases in pulse amplitude and frequency, nonpulsatile (basal) release, and irregularity. Whether sustained blockade by octreotide can restore physiological secretion patterns in this setting is unknown. To address this question, we studied seven patients with GH-secreting tumors during chronic receptor agonism. Responses were monitored by sampling blood at 10-min intervals for 24 h, followed by analyses of secretion and regularity by multiparameter deconvolution and approximate entropy (ApEn). The somatostatin agonist suppressed GH secretory-burst mass, nonpulsatile (basal) GH release, and pulsatile secretion, thereby decreasing total GH secretion by 86% (range 70-96%). ApEn decreased from 1.203 ± 0.129 to 0.804 ± 0.141 (P = 0.032), denoting greater regularity. None of GH pulse frequency, basal GH secretion rates, or ApEn normalized. In summary, chronic somatostatin agonism is able to repress amplitude-dependent measures of excessive GH secretion in acromegaly. Presumptive tumoral autonomy is inferred by continued elevations of event frequency, overall pattern disruption (irregularity), and nonsuppressible basal GH secretion.

KW - Deconvolution analysis

KW - Diurnal rhythm

KW - Growth hormone

KW - Human

UR - http://www.scopus.com/inward/record.url?scp=0348048484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348048484&partnerID=8YFLogxK

M3 - Article

C2 - 14506078

AN - SCOPUS:0348048484

VL - 286

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1 49-1

ER -